These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The emerging role of novel therapies for the treatment of relapsed myeloma. Richardson PG; Hideshima T; Mitsiades C; Anderson KC J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684 [TBL] [Abstract][Full Text] [Related]
3. Diagnosis and the current trends in multiple myeloma therapy. Dmoszyńska A Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817 [TBL] [Abstract][Full Text] [Related]
4. Lenalidomide for bortezomib-resistant multiple myeloma. Briani C; Berno T; Campagnolo M; Zambello R Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906 [No Abstract] [Full Text] [Related]
5. Lenalidomide efficacy in bortezomib-resistant myeloma. Gozzetti A; Crupi R; Defina M; Bocchia M Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907 [No Abstract] [Full Text] [Related]
6. Proteasome inhibitor therapy in multiple myeloma. Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343 [TBL] [Abstract][Full Text] [Related]
7. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Lacy MQ; Tefferi A Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284 [TBL] [Abstract][Full Text] [Related]